Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis

World Journal of Gastroenterology

Volumn 15, Issue 35, 2009, Pages 4387-4391

  Yilmaz, Yusuf ^a   Kedrah, Alla Eldeen ^a   Ozdogan, Osman ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Biomarkers; Liver biopsy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOPOIETIN LIKE PROTEIN 3; CYTOKERATIN 18; LEPTIN; PENTRAXIN 3; PLASMA PROTEIN; RESISTIN; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; DIAGNOSTIC VALUE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 72049105082     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4387     Document Type: Review

References (54)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
2. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50: 171-180 (Pubitemid 40379159)
3. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698
4. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009; 50 Suppl: S412-S416
5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 (Pubitemid 41002048)
6. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 (Pubitemid 46489550)
7. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008; 28: 386-395
8. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589 (Pubitemid 47344794)
9. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005; 10: 3093-3099
10. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-379
11. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761 (Pubitemid 44917301)
12. Baranova A, Liotta L, Petricoin E, Younossi ZM. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis 2007; 11: 209-220, xi (Pubitemid 46829968)
13. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443 (Pubitemid 36929425)
14. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33 (Pubitemid 44049136)
15. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-1437
16. Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008; 47: 481-485
17. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844 (Pubitemid 46470292)
18. Yilmaz Y, Ulukaya E, Dolar E. Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology 2009; 49: 697; author reply 697
19. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721-728
20. Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 2008; 6: 1-7
21. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-427 (Pubitemid 41017626)
22. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-1433 (Pubitemid 36007818)
23. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188
24. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998; 244: 178-182 (Pubitemid 28419920)
25. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-409 (Pubitemid 34810360)
26. Huang XD, Fan Y, Zhang H, Wang P, Yuan JP, Li MJ, Zhan XY. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2008; 14: 2888-2893
27. Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, Erensoy A. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006; 2006: 34295 (Pubitemid 44826824)
28. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-3589
29. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, Hamasaki K, Kato Y, Eguchi K, Yukawa K, Ishii N. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002; 97: 1796-1801 (Pubitemid 34761409)
30. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-949 (Pubitemid 39575661)
31. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008; 15: 565-576
32. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792 (Pubitemid 44033298)
33. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 (Pubitemid 38056380)
34. Gil-Campos M, Cañete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974 (Pubitemid 39243008)
35. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-703 (Pubitemid 40006789)
36. Aygun C, Senturk O, Hulagu S, Uraz S, Celebi A, Konduk T, Mutlu B, Canturk Z. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2006; 18: 175-180 (Pubitemid 43361603)
37. Yoon D, Lee SH, Park HS, Lee JH, Park JS, Cho KH, Kim SM. Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. J Korean Med Sci 2005; 20: 421-426 (Pubitemid 40908921)
38. Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, Asimakopoulos S, Labropoulou- Karatza C. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg 2008; 71: 355-360
39. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L. Serum adipokine levels predictive of liver injury in nonalcoholic fatty liver disease. Liver Int 2009; 1431-1438
40. Cho YK, Lee WY, Oh SY, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Kim SW, Oh KW, Yun EJ, Oh ES. Factors affecting the serum levels of adipokines in Korean male patients with nonalcoholic fatty liver disease. Hepatogastroenterology 2007; 54: 1512-1516
41. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006; 17: 170-175
42. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 2005; 109: 243-256 (Pubitemid 41337128)
43. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M, Avellini C, Federspil G, Sechi LA, Vettor R. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086 (Pubitemid 43357784)
44. Jiang LL, Li L, Hong XF, Li YM, Zhang BL. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 2009; 21: 662-666
45. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-1978
46. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009; 42: 802-807
47. Li C. A tale of two angiopoietin-like proteins. Curr Opin Lipidol 2007; 18: 597-599
48. Yilmaz Y, Ulukaya E, Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol 2009; Epub ahead of print
49. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008; 20: 538-544
50. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008; 8: 53
51. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665-674 (Pubitemid 41233660)
52. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH, Bedossa P, Paradis V. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009; 58: 825-832
53. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008; 48: 2086-2087; author reply 2087
54. Yilmaz Y, Ulukaya E, Dolar E. A "biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. Obes Surg 2008; 18: 1507-1508; author reply 1509-1510